他汀类药物对慢性肝脏疾病进展及预后的影响  

Effect of statins on the progression and prognosis of chronic liver diseases

作　　者：王帅[1] 张永贵[1] 王江滨[1] 徐严[1] WANG Shuai;ZHANG Yonggui;WANG Jiangbin;XU Yan(Department of Gastroenterology, China-Japan Union Hospital of Jilin University, Changchun 130033, China)

机构地区：[1]吉林大学中日联谊医院消化内科,长春130033

出　　处：《临床肝胆病杂志》2021年第3期721-724,共4页Journal of Clinical Hepatology

基　　金：国家自然科学基金(81670533);吉林省教育厅资助项目(JJKH20190067KJ)。

摘　　要：慢性肝病严重时可进展为肝纤维化和肝硬化,进而引起门静脉高压,最终可能发展至肝细胞癌。近年来,越来越多的研究发现他汀类药物可以使非酒精性脂肪性肝病患者的肝脏组织学得到改善,延缓肝纤维化进展,降低失代偿事件以及肝细胞癌的发生风险。介绍了他汀类药物在慢性肝病患者中的应用进展,为慢性肝脏疾病的防治提供一定的依据。Chronic liver diseases can progress to liver fibrosis and cirrhosis and may lead to portal hypertension and even hepatocellular carcinoma.In recent years,more and more studies have shown that statins can improve liver histology,delay progression to liver fibrosis,and reduce the risk of decompensation and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.This article introduces the advances in the application of statins in patients with chronic liver diseases,so as to provide a basis for the prevention and treatment of chronic liver diseases.

关 键 词：肝疾病 羟甲基戊二酰基COA还原酶抑制剂 治疗结果 预后 

分 类 号：R575[医药卫生—消化系统]